1. Home
  2. STEX vs ELDN Comparison

STEX vs ELDN Comparison

Compare STEX & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STEX

Streamex Corp.

N/A

Current Price

$2.04

Market Cap

297.8M

Sector

N/A

ML Signal

N/A

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

N/A

Current Price

$2.93

Market Cap

208.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STEX
ELDN
Founded
2009
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
297.8M
208.6M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
STEX
ELDN
Price
$2.04
$2.93
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$12.00
$8.50
AVG Volume (30 Days)
2.0M
792.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.27
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.98
$1.35
52 Week High
$7.44
$4.60

Technical Indicators

Market Signals
Indicator
STEX
ELDN
Relative Strength Index (RSI) 35.51 74.86
Support Level N/A $2.91
Resistance Level $3.68 $3.27
Average True Range (ATR) 0.20 0.20
MACD 0.01 0.05
Stochastic Oscillator 14.00 80.84

Price Performance

Historical Comparison
STEX
ELDN

About STEX Streamex Corp.

Streamex Corp is a vertically integrated technology and infrastructure company. It is focused on the tokenization and digitalization of real-world assets. The group provides institutional-grade solutions that bring traditional commodities and assets on-chain through secure, regulated, and yield-bearing financial instruments. It is committed to delivering transparent, scalable, and compliant digital asset solutions that bridge the gap between traditional finance and blockchain-enabled markets.

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Share on Social Networks: